Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study

David W Dempster; Hua Zhou; Robert R Recker; Jacques P Brown; Christopher P Recknor; E Michael Lewiecki; Paul D Miller; Sudhaker D Rao; David L Kendler; Robert Lindsay; John H Krege; Jahangir Alam; Kathleen A Taylor; Boris Janos; Valerie A Ruff

doi:10.1210/jc.2015-4181

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study

J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181. Epub 2016 Feb 9.

Authors

Affiliation

¹ Regional Bone Center (D.W.D., H.Z., R.L.), Helen Hayes Hospital, West Haverstraw, New York; Department of Pathology and Cell Biology (D.W.D.), College of Physicians and Surgeons of Columbia University, New York; Department of Medicine (R.R.R.), Division of Endocrinology, School of Medicine, Creighton University, Omaha, Nebraska; Rheumatology and Bone Diseases Research Group (J.P.B.), CHU de Quebec (CHUL) Research Centre and Department of Medicine, Laval University, Quebec City, Quebec, Canada; United Osteoporosis Centers (C.P.R.), Gainesville, Georgia; New Mexico Clinical Research & Osteoporosis Center (E.M.L.), Albuquerque, New Mexico; Department of Medicine (P.D.M.), Colorado Center for Bone Research, Lakewood, Colorado; Bone & Mineral Research Laboratory (S.D.R.), Henry Ford Hospital, Detroit, Michigan; Department of Medicine (Endocrinology) (D.L.K.), University of British Columbia, Vancouver, British Columbia, Canada; Department of Medicine (R.L.), College of Physicians and Surgeons of Columbia University, New York; Lilly Research Laboratories (J.H.K., J.A.), Eli Lilly and Company, Indianapolis, Indiana; Musculoskeletal and Men's Health (K.A.T., V.A.R.), Lilly USA, LLC, Indianapolis, Indiana; Research and Development - Bio-Medicines (B.J.), Eli Lilly Canada Inc., Toronto, Ontario, Canada.

Abstract

We compared effects of teriparatide and denosumab on PTH, bone turnover markers, and bone histomorphometry in osteoporotic postmenopausal women. The findings were inconsistent with an early indirect anabolic effect of denosumab.

Publication types

Comparative Study
Randomized Controlled Trial

MeSH terms

Aged
Aged, 80 and over
Anabolic Agents
Bone Density Conservation Agents / therapeutic use*
Denosumab / therapeutic use*
Drug Therapy, Combination
Female
Humans
Middle Aged
Osteogenesis / drug effects*
Osteoporosis, Postmenopausal / drug therapy*
Osteoporosis, Postmenopausal / metabolism
Osteoporosis, Postmenopausal / pathology
Parathyroid Hormone / metabolism*
Teriparatide / therapeutic use*

Substances

Anabolic Agents
Bone Density Conservation Agents
Parathyroid Hormone
Teriparatide
Denosumab

Grants and funding

R01 AR062103/AR/NIAMS NIH HHS/United States